Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. - Wikidata - awgldk - TriplyDB

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

http://www.wikidata.org/entity/Q34339563

about

Ivacaftor for patients with cystic fibrosis Update in Cystic Fibrosis 2014 Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications New and emerging targeted therapies for cystic fibrosis Targeted therapies to improve CFTR function in cystic fibrosis CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms Evaluation of the impact of alveolar nitrogen excretion on indices derived from multiple breath nitrogen washout.Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings.Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.Improved Growth Patterns in Cystic Fibrosis Mice after Loss of Histone Deacetylase 6.Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.CFTR Modulators for the Treatment of Cystic Fibrosis.Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation.Recent advances in the management of cystic fibrosis.Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Ivacaftor: a novel mutation modulating drug PharmGKB summary: very important pharmacogene information for CFTR Enhanced photoacoustic gas analyser response time and impact on accuracy at fast ventilation rates during multiple breath washout.Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report.Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770).Improved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compounds.Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency.Cystic fibrosis: a model system for precision medicine.Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor Pseudomonas aeruginosa biofilms in disease.Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.Ivacaftor: a review of its use in patients with cystic fibrosis.The impact of germline mutations on targeted therapy.Malnutrition in cystic fibrosis: a review.

P2860

Q22305938-1B9FF982-E45C-48B7-AED8-5B3B3B40CC53 Q22306307-D235DCA1-0E85-48FF-9EE4-6F6D60C70242 Q24187139-0BDDAEB5-D346-4452-8E15-CA699F103A12 Q26747065-181394D8-E39C-4919-9BA8-8BF4C183DE7A Q26749278-3A0BB94E-B38A-47FD-802D-6586EDEF7F4B Q26781441-24EB1A69-193F-47DB-A2DC-A52A2FFB99EA Q28073996-CB27217D-CBC0-411A-8A93-BAC903926DBE Q28077411-D101BB0D-47C2-46E5-BB74-34EACC292684 Q31138673-6A19647E-F05E-4B41-8872-58A7E30017C2 Q33470424-F86D72D0-18C0-4558-97C5-A0D809A7B004 Q33633486-2568B8A2-86C3-486B-8626-4A261B537610 Q33769791-D4D57DA4-9332-4CD7-8C95-263CCA02C6DF Q33807836-29DAF305-197F-4DFC-9C56-E58A416D3FD9 Q33865292-9B565AA6-BA41-4C14-B9F0-E512E8B9F53D Q33920366-7FCAAADF-2BFD-48FB-8D31-02F7251D7B32 Q34117376-708EA335-CD24-48B7-AEDE-649277D3767C Q34286307-12DE3D1A-8743-42D1-91B5-DA75DBABE51B Q34427981-D0F168D1-9D7A-4E52-8E03-7444D941EEFF Q34480471-566A031C-24B9-4773-B4C9-492E0C94611E Q34496122-1D617F10-D506-4B26-BE81-F8D7E99924C9 Q34667499-73E07A2C-6167-4371-A040-0DD056F760D8 Q35108743-0F8A6AA5-C92B-4C9A-A3DD-037C0EB7581F Q35180616-C6E79785-8C82-45C6-9A99-0295E16C0625 Q35326173-0487EF38-07E3-4C8D-A803-CDFEF8EB6815 Q35810699-1491779E-77BD-4D5D-B0AE-AA62E2BA056F Q36232717-9EC869A0-5D08-4B79-973F-4ED78443717B Q36251047-C84ECE63-797C-4C27-8430-03ADA517DFA7 Q36269320-6E2B0D95-996D-4492-84F0-DC771488CEC9 Q36609344-9FBB9C6D-13FB-4C9E-B046-B073BD2375EB Q36865792-CA0B85FE-63EE-4570-B642-1CF47319DF42 Q37055879-CB6F2BAF-3EAE-4AD9-BAD5-DB9524EAEE18 Q37097931-13D7F911-11BF-47DA-9476-867A89F410B4 Q37241563-311492F2-4495-4205-84FB-5CCCC558A9F5 Q37602780-23F27085-D5D8-46B4-82D1-826AA8AE0C4A Q37687126-67B8AEAE-7F1B-4128-891F-6FD5B1190513 Q38113749-8D07ECCC-AC7C-4C8C-8621-5E002B3A84E9 Q38134182-87BFDA31-57A0-4B3D-8E47-333C74576F57 Q38136994-8E34317B-F475-4146-B0C0-A9FF3E06F33F Q38151546-94ABC010-ECE2-4707-B8CF-9CCCC0508C32 Q38156392-A5210B05-4F40-45EA-8913-03F1C60EBE1B

P2860

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

http://www.wikidata.org/entity/Q34339563

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@ast

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@en

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@nl

type

label

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@ast

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@en

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@nl

prefLabel

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@ast

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@en

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@nl

P1433

Q34339563-69634A5A-330D-4DDF-AABA-FB0CC291A217

P1476

Q34339563-303652F8-BAAC-4C3B-BB30-57B7EEE59A7A

P2093

Q34339563-03852807-BEFF-464F-A964-94E4D8F99762

Q34339563-1B99061E-0346-4B82-A19C-A0C1A48C5725

Q34339563-33A52074-CA3D-4A28-ACD7-29F4E7BEDF83

Q34339563-464AA2BA-1269-4C6D-929B-F63F79CF9A94

Q34339563-48AB0473-0D78-4024-98B0-068BE315BC7D

Q34339563-5DB41AA6-FE58-4BC1-9857-FA2D73B215F5

Q34339563-635F29BF-D05F-4721-83A9-3B761F66D80C

Q34339563-83FE2E5E-233C-4871-9826-A6C37D2FAAA8

Q34339563-A77C894E-6584-4C5C-A64A-9EFA07644E82

Q34339563-C3FB2588-BC18-48BE-BE8D-E793570168DD

P2860

Q34339563-0E3ECDFF-93F5-4550-A273-70C448A8C7C5

Q34339563-14C1D3F0-5DE9-4AF2-A492-BE65C55233E2

Q34339563-1AF9B797-913F-4222-ACA7-98ED87BD20B5

Q34339563-1DD2200F-7E0A-4ECC-A5A7-E8A5FA3ACEA1

Q34339563-37AB4850-40FD-4033-AB83-95AAE6577BCE

Q34339563-464ED7F7-1C0A-4C15-9303-692C88AC42C0

Q34339563-56FCB8D8-2480-4A84-B0D7-E16A31BE13B8

Q34339563-65519D0E-C2ED-4364-8B7F-4B52D9B3F80E

Q34339563-65E949E4-D5FE-4D3E-AF75-CB4B9AEF6F98

Q34339563-703BF2E3-FF2C-405C-BD4A-A393AB7DC73A

P304

Q34339563-548704F6-D021-4FFE-9182-3BF19FB74757

P31

Q34339563-6EDCC0DE-E9C2-49D8-9AFC-669149154127

P356

Q34339563-A3B8F2AD-4D2C-475F-878B-0696B0A3D520

P407

Q34339563-BC0FF8C2-9EA6-4D7C-B9E0-A288C4F488CA

P433

Q34339563-858D7C1E-7353-4AC7-B756-45CBDDF07BEB

P478

Q34339563-AEC12056-129A-493C-A5D7-162506E116A4

P50

Q34339563-512EB54D-D345-40D7-A40E-3F74BCA0DDA4

Q34339563-B6698898-0DB3-4B0C-9C47-4813527E78FC

P577

Q34339563-B60B2068-D3CE-4050-9809-562C562B7552

P698

Q34339563-4F0F18F1-600D-4DB8-9078-D28409895875

P921

Q34339563-13918D81-0039-4F43-B281-1BB226AE499D

Q34339563-471AC2D3-BA28-4751-910D-2D88D963F5C4

P932

Q34339563-72E14801-AB13-47E1-A25E-EDD4673F63E4

P356

RCCM.201301-0153OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Efficacy and safety of ivacaft ...... ibrosis with a G551D mutation.

@en

P2093

Anne Munck

http://www.w3.org/2001/XMLSchema#string

Claudia L Ordoñez

http://www.w3.org/2001/XMLSchema#string

Gerard J Canny

http://www.w3.org/2001/XMLSchema#string

Haihong Li

http://www.w3.org/2001/XMLSchema#string

Jane C Davies

http://www.w3.org/2001/XMLSchema#string

Karl Yen

http://www.w3.org/2001/XMLSchema#string

Mark A Chilvers

http://www.w3.org/2001/XMLSchema#string

Michelle S Howenstine

http://www.w3.org/2001/XMLSchema#string

Richard Ahrens

http://www.w3.org/2001/XMLSchema#string

Sally Rodriguez

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

Cystic fibrosis

Identification of the cystic fibrosis gene: genetic analysis

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

Pathogenesis of malnutrition in cystic fibrosis, and its treatment.

Changes in the normal maximal expiratory flow-volume curve with growth and aging.

P304

1219-1225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201301-0153OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

187

http://www.w3.org/2001/XMLSchema#string

P50

Claire Wainwright

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23590265

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

3734608

http://www.w3.org/2001/XMLSchema#string